Pharmacologic Management of Acute Spinal Cord Injury

被引：25

作者：

Karsy, Michael ^{[1
]}

Hawryluk, Gregory ^{[1
]}

机构：

[1] Univ Utah, Dept Neurosurg, Salt Lake City, UT USA

来源：

NEUROSURGERY CLINICS OF NORTH AMERICA | 2017年 / 28卷 / 01期

关键词：

Spinal cord injury; Secondary injury; Neuroprotective agent; Neuroregenerative agent; Methylprednisolone; Central nervous system; COLONY-STIMULATING FACTOR; PROMOTES AXONAL REGENERATION; MARROW-CELL TRANSPLANTATION; CENTRAL-NERVOUS-SYSTEM; GROWTH-FACTOR; FUNCTIONAL RECOVERY; PHASE-I; CONTROLLED-TRIAL; BFGF PROMOTES; RAT MODEL;

D O I：

10.1016/j.nec.2016.07.002

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Spinal cord injury is a serious global public health problem that often leaves patients with devastating permanent disabilities. Although advances in supportive care have improved outcome in recent decades, there remains great need for a safe and efficacious medical treatment that improves neurologic outcome. This article reviews pharmacologic treatments evaluated or in the process of development in humans. Cellular transplantation strategies are briefly reviewed especially where they have been evaluated with pharmacologic treatments. There is great hope that one or more of these new therapeutics will be successfully translated and improve the neurologic recovery of patients in the near future.

引用

页码：49 / +

页数：15

共 105 条

[1] Myelin associated inhibitors: A link between injury-induced and experience-dependent plasticity [J].